A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency

Interested by today’s topic of discussion in A&P, I decided to look for an article on the use of growth hormones on pediatric growth hormone deficiency. I found a study by Moore, et al. looked to explore the safety and efficacy of somavaratan in treating pediatric growth hormone deficiency. The study took 68 prepubescent children and randomly assigned them to doses of somavaratan. They were monitored for six months, which included a 30-day dose-finding phase. Somavaratan was found to help reduce the amount of injections of growth hormones the patients needed, up to only one injection per month.

As a pharmacist I think that this study was pretty helpful. Growth hormones can be very important for certain pediatric patients, but daily injections may be something a patient is not willing or able to adhere too. If the addition of somavaratan is continued to be researched and becomes an approved usage, it could do a lot to help patients who suffer from pediatric growth hormone stay adherent and could potentially reduce long term costs for the disorder. What did you think of the study? What do you think of using children in research to begin with?

Link to the article

Moore, Wayne V., Huong Jil Nguyen, Gad B. Kletter, Bradley S. Miller, Douglas Rogers, David Ng, Jerome A. Moore, Eric Humphriss, Jeffrey L. Cleland, and George M. Bright. “A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting RhGH, in Pediatric Growth Hormone Deficiency.” The Journal of Clinical Endocrinology & Metabolism 101.3 (2016): 1091-097. Web.